ArticleJBMR plus2026
Repeated romosozumab with short-term ibandronate sequencing in high-risk osteoporosis: a retrospective single-center cohort study.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term real-world evidence on repeated romosozumab treatment remains limited. This retrospective single-center cohort included 68 patients who initiated treatment between April 2020 and April 2026. Nineteen patients discontinued during the 5-yr observation period, and 49 completed follow-up and formed the longitudinal analytical cohort. Patients received romosozumab for 12 mo followed by oral ibandronate 100 mg once monthly for 3 mo before reassessment for another course. All patients received eldecalcitol 0.75 μg daily. Recorded LS and femoral young adult mean (YAM) values, bone turnover markers, numerical rating scale scores, persistence, fractures, and prespecified safety events were evaluated. Longitudinal outcomes were analyzed using linear mixed-effects models with a patient-level random intercept. Lumbar spine YAM increased from 73.3% at baseline to 92.9% at 5 yr, with a model-estimated change of 19.6 percentage points (95% CI, 17.9-21.3;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.